Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · Advisorshares

AdvisorShares Psychedelics ETF (PSIL)

Ticker PSIL · Since 2021-09-15 · · Holdings as of Jun 30, 2026

Expense ratio
1%$100/yr per $10k
1-yr return
+73.4%as of Dec 2025
Net assets
$44.4Mall share classes
Holdings
32

Bottom line

Is PSIL a good fund? The bottom line

PSIL is an actively managed large blend ETF from Advisorshares.

Its expense ratio is 1% — about $100 a year on every $10,000 invested, more expensive than 64% of large blend funds we track.

It returned +73.4% over one year (as of Dec 31, 2025, per its prospectus).

With $44.4 million in net assets and 32 holdings, its largest position is Definium Therapeutics Inc (12.9%) and the top 10 make up 69.2% of the portfolio.

What to watch

  • Concentrated: top 10 holdings are 69.2% of assets
  • Small fund ($44.4 million) — small funds are likelier to close

Updated Nov 19, 2026

What PSIL invests in

The AdvisorShares Psychedelics ETF (the Fund) seeks long-term capital appreciation.

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid-, small- and micro-capitalization companies. The Fund also may invest in total return swaps intended to provide exposure to such companies. Under normal circumstances, Fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. Psychedelic drugs, also known…

From the fund's prospectus (filed Oct 28, 2026).

PSIL performance

Fund calendar-year total returns, 2022–2025 2022: −66.0%; 2023: −24.5%; 2024: −19.4%; 2025: +73.4% −66.0% 2022 −24.5% 2023 −19.4% 2024 +73.4% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
PSIL+73.4%——
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full PSIL performance history →

What PSIL costs

On a $10,000 investment, PSIL's 1% expense ratio costs about $100 a year. The prospectus estimates $1,521 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full PSIL fee table →

PSIL top 10 holdings

#Holding% of fund
1Definium Therapeutics Inc DFTX12.85%
2Compass Pathways Plc CMPS11.45%
3Ataibeckley Inc ATAI10.47%
4Relmada Therapeutics Inc RLMD6.84%
5Nrx Pharmaceuticals Inc NRXP6.07%
6Neurocrine Biosciences Inc NBIX4.38%
7Cybin Inc HELP4.35%
8Gh Research Plc GHRS4.31%
9Alkermes Plc ALKS4.30%
10Alto Neuroscience Inc ANRO4.20%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 69.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to PSIL

More funds like PSIL →

PSIL FAQ

What is the expense ratio of PSIL?
PSIL's expense ratio is 1%, which works out to about $100 a year for every $10,000 invested. The prospectus estimates total costs of $1,521 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PSIL a good investment?
It depends on your goals, but the data points to: concentrated: top 10 holdings are 69.2% of assets; small fund ($44.4 million) — small funds are likelier to close. This is general information, not personalized advice.
What does PSIL hold?
PSIL's largest holdings are Definium Therapeutics Inc (12.9%), Compass Pathways Plc (11.5%), Ataibeckley Inc (10.5%), Relmada Therapeutics Inc (6.8%), Nrx Pharmaceuticals Inc (6.1%). It holds 32 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages PSIL?
PSIL is offered by Advisorshares through AdvisorShares Trust.